---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-006671"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:47:21.498534+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aligos Q3 net loss $18.0M ($0.41/shr); raises $92M in October PIPE

## Summary
- Net loss $18.0M ($0.41 per share) vs $18.6M ($0.44) in Q3 2022.
- Cash, equivalents & investments $70.4M at Sep 30, down from $125.8M at Dec 31, 2022.
- Closed $92M private placement in October 2023; projects cash runway through end of 2025.
- FDA cleared IND for NASH THR-β agonist ALG-055009; Phase 2a startup underway.
- Awarded $8.5M NIAID contract to advance coronavirus protease inhibitor ALG-097558.

## SEC filing metadata
- accession: 0001171843-23-006671
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000117184323006671/0001171843-23-006671-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000117184323006671/f8k_110223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-006671
- JSON: https://secwatch.observer/filing/0001171843-23-006671.json
- Plain text: https://secwatch.observer/filing/0001171843-23-006671.txt

## Key facts
- Earnings Releases
  Aligos Therapeutics, Inc. reported the third quarter 2023 results: net income $18.0 million, EPS $(0.41).
  - Period: the third quarter 2023
  - Net income: $18.0 million
  - EPS: $(0.41)
  - Result: reported results
  source text: Net losses for the three months ended September 30, 2023 were $18.0 million or basic and diluted net loss per common share of $(0.41)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000117184323006671/0001171843-23-006671-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.